Thomas C Wirth
Overview
Explore the profile of Thomas C Wirth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peter M, Mundt B, Menze A, Woller N, Volk V, Ernst A, et al.
EMBO Mol Med
. 2025 Jan;
17(2):265-300.
PMID: 39789356
Oncolytic viruses (OV) expressing bispecific T-cell engagers (BiTEs) are promising tools for tumor immunotherapy but the range of target tumors is limited. To facilitate effective T-cell stimulation with broad-range applicability,...
2.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, et al.
Hepatol Commun
. 2024 Nov;
8(11).
PMID: 39495153
Background: Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use...
3.
Mahlmann J, Wirth T, Hartleben B, Schrem H, Mahlmann J, Kaltenborn A, et al.
Visc Med
. 2021 Jul;
37(3):198-205.
PMID: 34250077
Background: Hepatic steatosis and chemotherapy in the treatment of colorectal liver metastases (CLM) are often linked to increased mortality and morbidity after liver resection. This study evaluates the influence of...
4.
Ostroumov D, Duong S, Wingerath J, Woller N, Manns M, Timrott K, et al.
Hepatology
. 2020 Jul;
73(4):1399-1418.
PMID: 32716559
Background And Aims: Programmed death 1 (PD-1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of...
5.
Wirth T, Niemann J, Kuhnel F
EMBO Mol Med
. 2019 Nov;
12(1):e11496.
PMID: 31746105
Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint...
6.
Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin N, Kloos A, et al.
Nat Commun
. 2019 Jul;
10(1):3236.
PMID: 31324774
Virus-neutralizing antibodies are a severe obstacle in oncolytic virotherapy. Here, we present a strategy to convert this unfavorable immune response into an anticancer immunotherapy via molecular retargeting. Application of a...
7.
Wirth T, Kuhnel F
Front Immunol
. 2018 Jan;
8:1848.
PMID: 29312332
During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells. Initially, neoantigens were not recognized...
8.
Madadi-Sanjani O, Wirth T, Kuebler J, Petersen C, Ure B
Eur J Pediatr Surg
. 2017 Dec;
29(2):143-149.
PMID: 29258149
Previous research has confirmed that patients with choledochal cyst have an elevated risk of cholangiocarcinoma and gallbladder carcinoma. Current data suggest a risk of malignancy of 6 to 30% in...
9.
Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, et al.
Cancer Res
. 2017 Nov;
78(2):475-488.
PMID: 29180478
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and disseminating cancer resistant to therapy, including checkpoint immunotherapies, and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis....
10.
Wingerath J, Ostroumov D, Woller N, Manns M, Pinschewer D, Orlinger K, et al.
Mol Ther
. 2017 Aug;
25(11):2533-2545.
PMID: 28803862
Successful vaccination against cancer and infectious diseases relies on the induction of adaptive immune responses that induce high-titer antibodies or potent cytoxic T cell responses. In contrast to humoral vaccines,...